

Haematologica  
HAEMATOL/2019/221333  
Version 3

Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients

Frédéric Baron, Fabio Efficace, Laura Cannella, Roel Willemze, Marco Vignetti, Petra Muus, Jean-Pierre Marie, Dario Ferrero, Paola Fazi, Edoardo La Sala, Jean-Henri Bourhis, Francesco Fabbiano, Alberto Bosi, Marco Sborgia, Giovanni Martinelli, Sebastian Wittnebel, Silvia Trisolini, Maria Concetta Petti, Constantijn J.M. Halkes, Walter J.F.M. van der Velden, Theo de Witte, Sergio Amadori, Robert A. Zittoun, and Stefan Suciu

Disclosures: FB has received travel grants from Celgene, Abbvie, Novartis and Sanofi. Sergio Amadori has consulting or advisory role for Novartis, Celgene and Abbvie. Theo de Witte received support from Novartis and Celgene. Fabio Efficace received consultancy fee from Seattle Genetics, Bristol-Myers Squibb, TEVA, Orsenix and Incyte and research funding from Lundbeck, TEVA and Amgen. The other authors have nothing to disclose with respect to this manuscript.

Contributions: Conception and design: All authors. Manuscript writing: Frédéric Baron, Fabio Efficace, Stefan Suciu. Manuscript revising / editing: All others. Data analysis, collection and/or interpretation: All authors. Final approval of manuscript and agreement to be accountable for all aspect of the work: All authors.